Table 2 Empiric antibiotics therapy utilization and conversion practice in management of FN in pediatric oncology ward of TASH (N = 135)
Item description | N (%) |
|---|---|
Empiric antibiotics therapy indicated | |
 Ceftriaxone + gentamycin | 97 (71.8) |
 Cefepime + gentamycin | 4 (3.0) |
 Ceftazidime + vancomycin | 3 (2.2) |
 Ceftriaxone | 6 (4.4) |
 Ceftriaxone + vancomycin | 5 (3.7) |
 Cefepime + vancomycin | 4 (3.0) |
 Meropenem + ciprofloxacin | 2 (1.5) |
 Meropenem + gentamycin | 1 (0.7) |
 Piperacilin/tazobactam | 4 (3.0) |
 Meropenem + vancomycin | 4 (3.0) |
 Othersa | 5 (3.7) |
Duration of empiric antibiotics therapy | |
 < 7 days | 60 (44.4) |
 > 7 to ≤ 14 days | 66 (48.9) |
 > 14 days | 8 (5.9) |
Antibiotic conversion status | |
 First time conversion | 20 (14.8) |
 Second time conversion | 2 (1.5) |
First time conversion | |
 Monotherapy | 3 (2.2) |
 Combination therapy | 17 (12.6) |
Second time conversion | |
 Monotherapy | 1 (0.7) |
 Combination therapy | 1 (0.7) |